Moxonidine (BioDeep_00000002540)

 

Secondary id: BioDeep_00000405910

human metabolite Chemicals and Drugs


代谢物信息卡片


4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine

化学式: C9H12ClN5O (241.0730332)
中文名称: 莫索尼定
谱图信息: 最多检出来源 Mentha canadensis(plant) 75%

分子结构信息

SMILES: CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
InChI: InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)

描述信息

Moxonidine (INN) is a new generation centrally acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is manufactured by Solvay Pharmaceuticals under the brand name Physiotens. Moxonidine is a selective agonist at the imidazoline receptor subtype 1 (I1). This receptor subtype is found in both the rostral ventro-lateral pressor and ventromedial depressor areas of the medulla oblongata. Moxonidine therefore causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
C - Cardiovascular system > C02 - Antihypertensives > C02A - Antiadrenergic agents, centrally acting > C02AC - Imidazoline receptor agonists
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

同义名列表

11 个代谢物同义名

4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine; 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine; Solvay brand OF moxonidine; Lilly brand OF moxonidine; MOXONIDINE; Physiotens; Normatens; Moxonidin; Moxon; Cynt; Zint



数据库引用编号

16 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yutang Wang, Dinh Tam Nguyen, Jack Anesi, Ahmed Alramahi, Paul K Witting, Zhonglin Chai, Abdul Waheed Khan, Jason Kelly, Kate M Denton, Jonathan Golledge. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. International journal of molecular sciences. 2023 Feb; 24(4):. doi: 10.3390/ijms24043857. [PMID: 36835270]
  • Shaimaa S El-Sayed, Samar Rezq, Amira Ebrahim Alsemeh, Mona F Mahmoud. Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy. Life sciences. 2023 Jan; 312(?):121210. doi: 10.1016/j.lfs.2022.121210. [PMID: 36410408]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Sònia Abás, Sergio Rodríguez-Arévalo, Andrea Bagán, Christian Griñán-Ferré, Foteini Vasilopoulou, Iria Brocos-Mosquera, Carolina Muguruza, Belén Pérez, Elies Molins, F Javier Luque, Pilar Pérez-Lozano, Steven de Jonghe, Dirk Daelemans, Lieve Naesens, José Brea, M Isabel Loza, Elena Hernández-Hernández, Jesús A García-Sevilla, M Julia García-Fuster, Milica Radan, Teodora Djikic, Katarina Nikolic, Mercè Pallàs, Luis F Callado, Carmen Escolano. Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease. Journal of medicinal chemistry. 2020 04; 63(7):3610-3633. doi: 10.1021/acs.jmedchem.9b02080. [PMID: 32150414]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Ashraf H Ahmed, Richard D Gordon, Gregory Ward, Martin Wolley, Brett C McWhinney, Jacobus P Ungerer, Michael Stowasser. Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers. The Journal of clinical endocrinology and metabolism. 2017 06; 102(6):2039-2043. doi: 10.1210/jc.2016-3821. [PMID: 28324033]
  • O D Ostroumova, A A Zykova. [Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine]. Kardiologiia. 2016 10; 56(10):72-79. doi: 10.18565/cardio.2016.10.72-79. [PMID: 28290898]
  • Shaimaa S El-Sayed, Mohamed N M Zakaria, Rasha H Abdel-Ghany, Abdel A Abdel-Rahman. Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats. European journal of pharmacology. 2016 Jul; 783(?):73-84. doi: 10.1016/j.ejphar.2016.04.054. [PMID: 27138707]
  • Lubica Cibickova, Tomas Caran, Martin Dobias, Peter Ondra, Viktor Vorisek, Norbert Cibicek. Multi-drug intoxication fatality involving atorvastatin: A case report. Forensic science international. 2015 Dec; 257(?):e26-e31. doi: 10.1016/j.forsciint.2015.09.020. [PMID: 26508377]
  • Surbhi Gupta, Bhupesh Sharma. Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. Brain research bulletin. 2014 Mar; 102(?):57-68. doi: 10.1016/j.brainresbull.2014.02.007. [PMID: 24582883]
  • Hidenobu Tsutsui, Takahiro Sugiura, Kentaro Hayashi, Tokihito Yukimura, Mamoru Ohkita, Masanori Takaoka, Yasuo Matsumura. Protective effect of moxonidine on ischemia/reperfusion-induced acute kidney injury through α2/imidazoline I1 receptor. European journal of pharmacology. 2013 Oct; 718(1-3):173-80. doi: 10.1016/j.ejphar.2013.08.036. [PMID: 24041924]
  • Miklós Palkovits, Katarína Šebeková, Kristina Simon Klenovics, Anton Kebis, Gholamreza Fazeli, Udo Bahner, August Heidland. Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine. PloS one. 2013; 8(6):e66543. doi: 10.1371/journal.pone.0066543. [PMID: 23818940]
  • Murat Yigiter, Abdullah Yildiz, Beyzagul Polat, Hamit Hakan Alp, Osman Nuri Keles, Ahmet Bedii Salman, Halis Suleyman. The protective effects of metyrosine, lacidipine, clonidine, and moxonidine on kidney damage induced by unilateral ureteral obstruction in rats. Surgery today. 2012 Nov; 42(11):1051-60. doi: 10.1007/s00595-011-0074-8. [PMID: 22202971]
  • Lincoln P Edwards, Terry A Brown-Bryan, Lancelot McLean, Paul Ernsberger. Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovascular therapeutics. 2012 Aug; 30(4):199-208. doi: 10.1111/j.1755-5922.2011.00268.x. [PMID: 21884003]
  • Osama F Harraz, Hanan M El-Gowelli, Mahmoud M Mohy El-Din, Abdel-Rheem M Ghazal, Mahmoud M El-Mas. Adenosinergic modulation of the imidazoline I₁-receptor-dependent hypotensive effect of ethanol in acute renal failure. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2012 Aug; 50(8):2622-8. doi: 10.1016/j.fct.2012.05.015. [PMID: 22613216]
  • Gianfranco Parati, Murray Esler. The human sympathetic nervous system: its relevance in hypertension and heart failure. European heart journal. 2012 May; 33(9):1058-66. doi: 10.1093/eurheartj/ehs041. [PMID: 22507981]
  • Ankur Gupta, Bakshish Singh. Moxonidine-induced priapism in an autosomal-dominant polycystic kidney disease dialysis patient. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2012 May; 23(3):588-9. doi: NULL. [PMID: 22569452]
  • C A F Andrade, L O Margatho, G M F Andrade-Franzé, L A De Luca, J Antunes-Rodrigues, J V Menani. Moxonidine into the lateral parabrachial nucleus reduces renal and hormonal responses to cell dehydration. Neuroscience. 2012 Apr; 208(?):69-78. doi: 10.1016/j.neuroscience.2012.02.013. [PMID: 22373877]
  • Megumi Fujita, Katsuyuki Ando, Hiroo Kawarazaki, Chiaki Kawarasaki, Kazuhiko Muraoka, Hiroshi Ohtsu, Hideki Shimizu, Toshiro Fujita. Sympathoexcitation by brain oxidative stress mediates arterial pressure elevation in salt-induced chronic kidney disease. Hypertension (Dallas, Tex. : 1979). 2012 Jan; 59(1):105-12. doi: 10.1161/hypertensionaha.111.182923. [PMID: 22083162]
  • Paul A Sobotka, Felix Mahfoud, Markus P Schlaich, Uta C Hoppe, Michael Böhm, Henry Krum. Sympatho-renal axis in chronic disease. Clinical research in cardiology : official journal of the German Cardiac Society. 2011 Dec; 100(12):1049-57. doi: 10.1007/s00392-011-0335-y. [PMID: 21688196]
  • H Aceros, G Farah, L Cobos-Puc, A M Stabile, N Noiseux, S Mukaddam-Daher. Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt. British journal of pharmacology. 2011 Oct; 164(3):946-57. doi: 10.1111/j.1476-5381.2011.01355.x. [PMID: 21426316]
  • S I Kseneva, E V Borodulina, T A Semiglazova, N V Kulakova, I V Tarasova, O Ju Trifonova, T D Gridneva, V V Udut. Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome. Bulletin of experimental biology and medicine. 2011 Aug; 151(4):400-4. doi: 10.1007/s10517-011-1341-9. [PMID: 22448351]
  • M Voskuil, W L Verloop, P J Blankestijn, P Agostoni, P R Stella, P A Doevendans. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2011 Aug; 19(7-8):319-23. doi: 10.1007/s12471-011-0143-z. [PMID: 21567219]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • J Krupicka, M Soucek, K Chroust. [The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)]. Vnitrni lekarstvi. 2011 Jun; 57(6):541-5. doi: . [PMID: 21751539]
  • Angelita Maria Stabile, Henry Aceros, Kim Stockmeyer, Abdel A Abdel Rahman, Nicolas Noiseux, Suhayla Mukaddam-Daher. Functional and molecular effects of imidazoline receptor activation in heart failure. Life sciences. 2011 Mar; 88(11-12):493-503. doi: 10.1016/j.lfs.2011.01.008. [PMID: 21277868]
  • Jun-Feng Peng, Zhao-Tang Wu, Yang-Kai Wang, Wen-Jun Yuan, Tao Sun, Xin Ni, Ding-Feng Su, Wei Wang, Ming-Juan Xu, Wei-Zhong Wang. GABAergic mechanism in the rostral ventrolateral medulla contributes to the hypotension of moxonidine. Cardiovascular research. 2011 Feb; 89(2):473-81. doi: 10.1093/cvr/cvq289. [PMID: 20829217]
  • Sebastian Kummer, Stefanie Jeruschke, Lara Vanessa Wegerich, Andrea Peters, Petra Lehmann, Annette Seibt, Friederike Mueller, Nadezda Koleganova, Elisabeth Halbenz, Claus Peter Schmitt, Markus Bettendorf, Ertan Mayatepek, Marie-Luise Gross-Weissmann, Jun Oh. Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo. PloS one. 2011; 6(11):e27457. doi: 10.1371/journal.pone.0027457. [PMID: 22096576]
  • Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, Dimitri P Mikhailidis. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. The open cardiovascular medicine journal. 2011; 5(?):85-9. doi: 10.2174/1874192401105010085. [PMID: 21769302]
  • Fuad Lechin, Bertha van der Dijs, Betty Pardey-Maldonado, Jairo E Rivera, Scarlet Baez, Marcel E Lechin. Anorexia nervosa depends on adrenal sympathetic hyperactivity: opposite neuroautonomic profile of hyperinsulinism syndrome. Diabetes, metabolic syndrome and obesity : targets and therapy. 2010 Sep; 3(?):311-7. doi: 10.2147/dmsott.s10744. [PMID: 21437100]
  • Martin Hausberg, Faruk Tokmak, Hermann Pavenstädt, Bernhard K Krämer, Lars Christian Rump. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. Journal of hypertension. 2010 Sep; 28(9):1920-7. doi: 10.1097/hjh.0b013e32833c2100. [PMID: 20634720]
  • Ron J Keizer, Anubha Gupta, Melvin R Mac Gillavry, Mendel Jansen, Jantien Wanders, Jos H Beijnen, Jan H M Schellens, Mats O Karlsson, Alwin D R Huitema. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of pharmacokinetics and pharmacodynamics. 2010 Aug; 37(4):347-63. doi: 10.1007/s10928-010-9164-2. [PMID: 20652729]
  • Magda A Nasr, Sahar M El-Gowilly, Mahmoud M El-Mas. Comparable renovascular protective effects of moxonidine and simvastatin in rats exposed to cigarette smoke. Vascular pharmacology. 2010 Jul; 53(1-2):53-60. doi: 10.1016/j.vph.2010.03.006. [PMID: 20350618]
  • Anna Masajtis-Zagajewska, Jacek Majer, Michał Nowicki. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. Hypertension research : official journal of the Japanese Society of Hypertension. 2010 Apr; 33(4):348-53. doi: 10.1038/hr.2010.6. [PMID: 20139920]
  • J Krupicka, M Soucek, K Chroust. [Combination therapy of hypertension in general clinical practice. The results of the KOHYBA study]. Vnitrni lekarstvi. 2010 Mar; 56(3):210-6. doi: . [PMID: 20394206]
  • Jia-ling Wang, Long Wang, Zhao-tang Wu, Wen-jun Yuan, Ding-feng Su, Xin Ni, Jian-jun Yan, Wei-zhong Wang. Low dose of moxonidine within the rostral ventrolateral medulla improves the baroreflex sensitivity control of sympathetic activity in hypertensive rat. Acta pharmacologica Sinica. 2009 Dec; 30(12):1594-600. doi: 10.1038/aps.2009.165. [PMID: 19960005]
  • Mahmoud M El-Mas, Hanan M El-Gowelli, Abdel-Rheem M Ghazal, Osama F Harraz, Mahmoud M Mohy El-Din. Facilitation of central imidazoline I(1)-site/extracellular signal-regulated kinase/p38 mitogen-activated protein kinase signalling mediates the hypotensive effect of ethanol in rats with acute renal failure. British journal of pharmacology. 2009 Nov; 158(6):1629-40. doi: 10.1111/j.1476-5381.2009.00444.x. [PMID: 19845670]
  • Jie Peng, Yang-Kai Wang, Li-Gang Wang, Wen-Jun Yuan, Ding-Feng Su, Xin Ni, Xiao-Ming Deng, Wei-Zhong Wang. Sympathoinhibitory mechanism of moxonidine: role of the inducible nitric oxide synthase in the rostral ventrolateral medulla. Cardiovascular research. 2009 Nov; 84(2):283-91. doi: 10.1093/cvr/cvp202. [PMID: 19535378]
  • Liaoyuan A Hu, Tian Zhou, Jinwoo Ahn, Shuli Wang, Julia Zhou, Yi Hu, Qingyun Liu. Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. The Biochemical journal. 2009 Oct; 424(1):39-45. doi: 10.1042/bj20090998. [PMID: 19725810]
  • H R Mehta, I K Patel, N H Patel, D M Patel, A B Parmar. Implication of enterohepatic re-circulation on single dose bioequivalence evaluation of two brands of clonidine hydrochloride tablets in healthy human volunteers. Indian journal of pharmaceutical sciences. 2009 Sep; 71(5):515-20. doi: 10.4103/0250-474x.58181. [PMID: 20502569]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Carina A F de Andrade, Glaucia M F de Andrade, Patricia M De Paula, Laurival A De Luca, José V Menani. Involvement of central alpha1-adrenoceptors on renal responses to central moxonidine and alpha-methylnoradrenaline. European journal of pharmacology. 2009 Apr; 607(1-3):60-7. doi: 10.1016/j.ejphar.2009.01.039. [PMID: 19326476]
  • Jiangang Yang, Naixue Sun, Quanchen Xiong, Rui Yang. Effect of moxonidine on the uveoscleral outflow: role of alpha2-adrenoceptors or i1 imidazoline receptors. Current eye research. 2009 Apr; 34(4):287-96. doi: 10.1080/02713680902750077. [PMID: 19373577]
  • Hidenobu Tsutsui, Takahiro Sugiura, Kentaro Hayashi, Mamoru Ohkita, Masanori Takaoka, Tokihito Yukimura, Yasuo Matsumura. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. European journal of pharmacology. 2009 Jan; 603(1-3):73-8. doi: 10.1016/j.ejphar.2008.12.012. [PMID: 19101535]
  • ". Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders. Cardiovascular journal of Africa. 2009 Jan; 20(1):73-4. doi: ". [PMID: 19287821]
  • A I Vengerovskiĭ, E M Idrisova, E A Bushkova, E I Mananko, N M Krasnova. [The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome]. Eksperimental'naia i klinicheskaia farmakologiia. 2008 Nov; 71(6):8-12. doi: . [PMID: 19140507]
  • P J Blankestijn, H Rupp. Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovascular & hematological agents in medicinal chemistry. 2008 Oct; 6(4):253-7. doi: 10.2174/187152508785909500. [PMID: 18855637]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • H Ebinç, Z N Ozkurt, F A Ebinç, D Ucardag, O Caglayan, M Yilmaz. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. The Journal of international medical research. 2008 Jan; 36(1):80-7. doi: 10.1177/147323000803600111. [PMID: 18230271]
  • E I Mananko, E V Vorob'eva, T P Kalashnikova, E A Bushkova, N M Krasnova, E M Idrisova, A I Vengerovskiĭ, R S Karpov, O V Gruzdeva, S V Kremenko. [The efficiency of combinations of Enalapril and long-acting Nifedipin and Moxonidine in patients with arterial hypertension and a metabolic syndrome]. Klinicheskaia meditsina. 2008; 86(7):56-61. doi: ". [PMID: 18756750]
  • Satomi Kagota, Yukari Tada, Yoko Kubota, Namie Nejime, Yu Yamaguchi, Kazuki Nakamura, Masaru Kunitomo, Kazumasa Shinozuka. Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. Journal of cardiovascular pharmacology. 2007 Dec; 50(6):677-85. doi: 10.1097/fjc.0b013e3181583d80. [PMID: 18091585]
  • Kavi J Littlewood, Wolfgang Greiner, Dominique Baum, York Zoellner. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC nephrology. 2007 Jul; 8(?):9. doi: 10.1186/1471-2369-8-9. [PMID: 17645811]
  • Giuseppe Derosa, Arrigo F G Cicero, Angela D'Angelo, Elena Fogari, Sibilla Salvadeo, Alessia Gravina, Ilaria Ferrari, Raffaella Fassi, Roberto Fogari. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Clinical therapeutics. 2007 Apr; 29(4):602-10. doi: 10.1016/j.clinthera.2007.03.015. [PMID: 17617283]
  • C A F Andrade, L A De Luca, D S A Colombari, J V Menani. Alpha2-adrenergic activation in the lateral parabrachial nucleus induces NaCl intake under conditions of systemic hyperosmolarity. Neuroscience. 2006 Sep; 142(1):21-8. doi: 10.1016/j.neuroscience.2006.04.015. [PMID: 16890365]
  • Irina Chazova, Vladimir A Almazov, Evgeny Shlyakhto. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes, obesity & metabolism. 2006 Jul; 8(4):456-65. doi: 10.1111/j.1463-1326.2006.00606.x. [PMID: 16776753]
  • A F Sanjuliani, V G de Abreu, E A Francischetti. Selective imidazoline agonist moxonidine in obese hypertensive patients. International journal of clinical practice. 2006 May; 60(5):621-9. doi: 10.1111/j.1368-5031.2006.00951.x. [PMID: 16700870]
  • Reza Mobini, Michael Fu, Per-Anders Jansson, Claes-Håkan Bergh, Margareta Scharin Täng, Finn Waagstein, Bert Andersson. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine. Clinical science (London, England : 1979). 2006 Mar; 110(3):329-36. doi: 10.1042/cs20050037. [PMID: 16209659]
  • Luhua Zhao, Li Ding, Xin Wei. Determination of moxonidine in human plasma by liquid chromatography-electrospray ionisation-mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2006 Jan; 40(1):95-9. doi: 10.1016/j.jpba.2005.06.002. [PMID: 16011885]
  • Peter Kotanko. Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood purification. 2006; 24(1):95-9. doi: 10.1159/000089444. [PMID: 16361848]
  • A B Bakhshaliev, G M Sabzalieva. [Comparison of the effectiveness of moxonidine and prestarium in postmenopausal women with mild and moderate arterial hypertension]. Klinicheskaia meditsina. 2006; 84(4):41-4. doi: . [PMID: 16755855]
  • Rodney A Velliquette, Rachel Kossover, Stephen F Previs, Paul Ernsberger. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn-Schmiedeberg's archives of pharmacology. 2006 Jan; 372(4):300-12. doi: 10.1007/s00210-005-0024-3. [PMID: 16416266]
  • Ergun Topal, Ayse Sertkaya Cikim, Kerim Cikim, Ismail Temel, Ramazan Ozdemir. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2006; 6(5):343-8. doi: 10.2165/00129784-200606050-00007. [PMID: 17083269]
  • Risto J Kaaja, Maritta K Pöyhönen-Alho. Insulin resistance and sympathetic overactivity in women. Journal of hypertension. 2006 Jan; 24(1):131-41. doi: 10.1097/01.hjh.0000194121.19851.e5. [PMID: 16331111]
  • Rouwayda El-Ayoubi, Ahmed Menaouar, Jolanta Gutkowska, Suhayla Mukaddam-Daher. Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist. British journal of pharmacology. 2005 May; 145(1):50-6. doi: 10.1038/sj.bjp.0706146. [PMID: 15700025]
  • Synnöve Lindemalm, Radojka M Savic, Mats O Karlsson, Gunnar Juliusson, Jan Liliemark, Freidoun Albertioni. Application of population pharmacokinetics to cladribine. BMC pharmacology. 2005 Mar; 5(?):4. doi: 10.1186/1471-2210-5-4. [PMID: 15757511]
  • José Abellán, Mariano Leal, Fernando Hernández-Menárguez, José A García-Galbis, Antonio Martínez-Pastor, Soledad Garcia de Vinuesa, José Luño. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney international. Supplement. 2005 Jan; ?(93):S20-4. doi: 10.1111/j.1523-1755.2005.09305.x. [PMID: 15613062]
  • Michael N Doumas, Stella N Douma, Kostas M Petidis, Kostas V Vogiatzis, Ilias C Bassagiannis, Chris X Zamboulis. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. Journal of clinical hypertension (Greenwich, Conn.). 2004 Dec; 6(12):682-9. doi: 10.1111/j.1524-6175.2004.03707.x. [PMID: 15599116]
  • Jutta Neumann, Gerry Ligtenberg, Liam Oey, Hein A Koomans, Peter J Blankestijn. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. Journal of the American Society of Nephrology : JASN. 2004 Nov; 15(11):2902-7. doi: 10.1097/01.asn.0000143471.10750.8c. [PMID: 15504943]
  • A M Sharma, T Wagner, P Marsalek. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. Journal of human hypertension. 2004 Sep; 18(9):669-75. doi: 10.1038/sj.jhh.1001676. [PMID: 15269705]
  • Oliver Vonend, Thomas Apel, Kerstin Amann, Lorenz Sellin, Johannes Stegbauer, Eberhard Ritz, Lars Christian Rump. Modulation of gene expression by moxonidine in rats with chronic renal failure. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2004 Sep; 19(9):2217-22. doi: 10.1093/ndt/gfh374. [PMID: 15266031]
  • S Mukaddam-Daher, J Gutkowska. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2004 Aug; 37(8):1239-45. doi: 10.1590/s0100-879x2004000800015. [PMID: 15273826]
  • Chunhua Cao, Chang Won Kang, Sung Zoo Kim, Suhn Hee Kim. Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy. American journal of physiology. Heart and circulatory physiology. 2004 Jul; 287(1):H150-6. doi: 10.1152/ajpheart.00977.2003. [PMID: 14975931]
  • S Jacob, H-J Klimm, K Rett, K Helsberg, H-U Häring, J Gödicke. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2004 Jun; 112(6):315-22. doi: 10.1055/s-2004-820915. [PMID: 15216449]
  • Alexis Gairard, Visitacion Lopez-Miranda, Fanny Pernot, Jean F Beck, Geneviève Coumaros, Bruno Van Overloop, Benoît La Roche, Christian Koehl, Marie O Christen. Effect of i1 imidazoline receptor agonist, moxonidine, in nitric oxide-deficient hypertension in pregnant rats. Journal of cardiovascular pharmacology. 2004 May; 43(5):731-6. doi: 10.1097/00005344-200405000-00017. [PMID: 15071362]
  • René R Wenzel, Anna Mitchell, Winfried Siffert, Sandra Bührmann, Thomas Philipp, Rafael F Schäfers. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress. British journal of clinical pharmacology. 2004 May; 57(5):545-51. doi: 10.1111/j.1365-2125.2003.02058.x. [PMID: 15089806]
  • P J Lumb, Z McMahon, G Chik, A S Wierzbicki. Effect of moxonidine on lipid subfractions in patients with hypertension. International journal of clinical practice. 2004 May; 58(5):465-8. doi: 10.1111/j.1368-5031.2004.00158.x. [PMID: 15206502]
  • Risto Kaaja, Karin Manhem, Jaakko Tuomilehto. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. International journal of clinical practice. Supplement. 2004 Mar; ?(139):26-32. doi: . [PMID: 15117110]
  • D A Anichkov, N A Shostak. [Effect of moxonidine on parameters of lipid metabolism in patients with metabolic syndrome.]. Kardiologiia. 2004; 44(9):13-5. doi: ". [PMID: 15477769]
  • A S Ametov, T Iu Demidova, L V Smagina. [The role of hypersympathycotony in development of arterial hypertension in patients with metabolic syndrome: potential of pathogenetically sound therapy]. Terapevticheskii arkhiv. 2004; 76(12):27-32. doi: ". [PMID: 15724921]
  • Gerhard J Molderings, Michael Bruss, Heinz Bonisch, Manfred Gothert. Identification and pharmacological characterization of a specific agmatine transport system in human tumor cell lines. Annals of the New York Academy of Sciences. 2003 Dec; 1009(?):75-81. doi: 10.1196/annals.1304.008. [PMID: 15028572]
  • S Mukaddam-Daher, A Menaouar, R El-Ayoubi, J Gutkowska, M Jankowski, R A Velliquette, P Ernsberger. Cardiac effects of moxonidine in spontaneously hypertensive obese rats. Annals of the New York Academy of Sciences. 2003 Dec; 1009(?):244-50. doi: 10.1196/annals.1304.030. [PMID: 15028594]
  • Rodney A Velliquette, Paul Ernsberger. Contrasting metabolic effects of antihypertensive agents. The Journal of pharmacology and experimental therapeutics. 2003 Dec; 307(3):1104-11. doi: 10.1124/jpet.103.054221. [PMID: 14557373]
  • Richard J Koletsky, Rodney A Velliquette, Paul Ernsberger. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Annals of the New York Academy of Sciences. 2003 Dec; 1009(?):251-61. doi: 10.1196/annals.1304.031. [PMID: 15028595]
  • D D Smyth, D Pirnat, B Forzley, S B Penner. Apparent absence of direct renal effect of imidazoline receptor agonists. Annals of the New York Academy of Sciences. 2003 Dec; 1009(?):288-95. doi: 10.1196/annals.1304.059. [PMID: 15028602]
  • Jay N Cohn, Marc A Pfeffer, Jean Rouleau, Norman Sharpe, Karl Swedberg, Matthias Straub, Curtis Wiltse, Theressa J Wright. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). European journal of heart failure. 2003 Oct; 5(5):659-67. doi: 10.1016/s1388-9842(03)00163-6. [PMID: 14607206]
  • Oliver Vonend, Parvaneh Marsalek, Hagen Russ, Ralf Wulkow, Vitus Oberhauser, Lars C Rump. Moxonidine treatment of hypertensive patients with advanced renal failure. Journal of hypertension. 2003 Sep; 21(9):1709-17. doi: 10.1097/00004872-200309000-00021. [PMID: 12923404]
  • Frédérique Touzeau, Axelle Arrault, Gérald Guillaumet, Elizabeth Scalbert, Bruno Pfeiffer, Marie-Claire Rettori, Pierre Renard, Jean-Yves Mérour. Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives. Journal of medicinal chemistry. 2003 May; 46(10):1962-79. doi: 10.1021/jm021050c. [PMID: 12723959]
  • Minxia M He, Trent L Abraham, Thomas J Lindsay, Hans C Schaefer, Isabelle J Pouliquen, Chris Payne, Boris Czeskis, Lisa A Shipley, Stuart D Oliver, Malcolm I Mitchell. Metabolism and disposition of the antihypertensive agent moxonidine in humans. Drug metabolism and disposition: the biological fate of chemicals. 2003 Mar; 31(3):334-42. doi: 10.1124/dmd.31.3.334. [PMID: 12584161]
  • E R Syrtlanova, L T Gil'mutdinova. [The use of moxonidine in patients with essential hypertension combined with metabolic syndrome]. Kardiologiia. 2003; 43(3):33-5. doi: NULL. [PMID: 12913980]
  • V V Trusov, K V Aksenov. [Effect of imidazoline receptor agonist moxonidine on the state of microcirculation and renal function in patients with hypertension and diabetes mellitus type 2]. Kardiologiia. 2003; 43(9):44-8. doi: NULL. [PMID: 14682297]
  • Fuad Lechin, Marcel Lechin, Bertha van der Dijs. Plasma catecholamines and chronic congestive heart failure. Circulation. 2002 Dec; 106(25):e222; author reply e222. doi: 10.1161/01.cir.0000043504.73472.7d. [PMID: 12485972]
  • Heinz Rupp, Richard Wahl, Bernhard Maisch, Matthias Hansen. Characterization of sucrose-induced changes in cardiac phenotype. Pflugers Archiv : European journal of physiology. 2002 Oct; 445(1):32-9. doi: 10.1007/s00424-002-0905-y. [PMID: 12397384]
  • Thomas Wenzl, Ernst P Lankmayr, Reinhold Wintersteiger, Anton Sadjak, Rudolf Likar, Dieter Zakel. Determination and quantification of clonidine in human blood serum. Journal of biochemical and biophysical methods. 2002 Oct; 53(1-3):131-9. doi: 10.1016/s0165-022x(02)00101-x. [PMID: 12406595]
  • Ahmed Menaouar, Rouwayda El-Ayoubi, Marek Jankowski, Jolanta Gutkowska, Suhayla Mukaddam-Daher. Chronic imidazoline receptor activation in spontaneously hypertensive rats. American journal of hypertension. 2002 Sep; 15(9):803-8. doi: 10.1016/s0895-7061(02)02971-0. [PMID: 12219876]
  • Stephen D Wise, Clark Chan, Hans G Schaefer, Minxia M He, Isabelle J Pouliquen, Malcolm I Mitchell. Quinidine does not affect the renal clearance of moxonidine. British journal of clinical pharmacology. 2002 Sep; 54(3):251-4. doi: 10.1046/j.1365-2125.2002.01647.x. [PMID: 12236844]
  • Hugues Greney, Dragan Urosevic, Stephan Schann, Laurence Dupuy, Véronique Bruban, Jean-Daniel Ehrhardt, Pascal Bousquet, Monique Dontenwill. [125I]2-(2-chloro-4-iodo-phenylamino)-5-methyl-pyrroline (LNP 911), a high-affinity radioligand selective for I1 imidazoline receptors. Molecular pharmacology. 2002 Jul; 62(1):181-91. doi: 10.1124/mol.62.1.181. [PMID: 12065769]
  • Karl Swedberg, Michael R Bristow, Jay N Cohn, Henry Dargie, Matthias Straub, Curtis Wiltse, Theressa J Wright. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002 Apr; 105(15):1797-803. doi: 10.1161/01.cir.0000014212.04920.62. [PMID: 11956122]
  • Angelos Halaris, He Zhu, Jeffery Ali, Amelia Nasrallah, C Lindsay De Vane, John E Piletz. Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment. The international journal of neuropsychopharmacology. 2002 Mar; 5(1):37-46. doi: 10.1017/s1461145701002759. [PMID: 12057030]
  • G De Vito, S D R Galloway, M A Nimmo, P Maas, J J V McMurray. Effects of central sympathetic inhibition on heart rate variability during steady-state exercise in healthy humans. Clinical physiology and functional imaging. 2002 Jan; 22(1):32-8. doi: 10.1046/j.1475-097x.2002.00395.x. [PMID: 12003097]